As requested by stakeholders, the deadline for the following CADTH calls for stakeholder input has been extended to November 9, 2015 at 5:00 p.m. EST:

CDR Update – Issue 111

CADTH Consultation: Revisions to the Common Drug Review Procedure

• Invites stakeholder comments and feedback on the following proposed revisions to the Procedure for the CADTH Common Drug Review (CDR):
• Revised deadline for voluntary withdrawal of CDR submissions and resubmissions
• Sharing of CADTH reviewers’ responses to manufacturer comments

CDR Update – Issue 112

Consultation on CADTH’s Common Drug Review (CDR) and pan-Canadian Oncology Drug Review (pCODR) Procedures

• Invites stakeholder comments on the proposed revisions to both the CADTH Common Drug Review (CDR) and the pan-Canadian Oncology Drug Review (pCODR) procedures on:
• A mandatory advance notification period for submitters/manufacturers of 180 calendar days
• Disclosure of the submitted price for drug products undergoing review by CADTH

Please click on the above links for more information.

CADTH: Extending Deadline on Consultation to Increase Opportunity for Clinician Input and Feedback in CADTH pan-Canadian Oncology Drug Review Process

As requested by stakeholders, the deadline on the proposed changes to the pan-Canadian Oncology Drug Review (pCODR) program that would allow for broader clinician participation in the pCODR process has been extended to November 30, 2015 at 5:00 p.m. ET:

In the current pCODR submission process, a total of three oncologists review clinical data, provide context and develop the main conclusions of the Clinical Guidance Report. Additional clinician input and feedback beyond that of the three Clinical Guidance Panel clinician members is not presently eligible for reconsideration by the pCODR Expert Review Committee (pERC), as there is no formal process for clinicians to comment on issues specific to local decision making. In view of the current situation, CADTH is proposing to develop a mechanism that would increase opportunities for clinicians to provide input and feedback and participate in the pCODR process.

Eligible clinicians must be registered with the pCODR program, be a recognized expert in the specific tumour site as evidenced by membership with a provincial cancer agency or a national cancer organization or similar body, be an active practising clinician treating the cancer type for the drug under review and submit a declaration of conflict of interests (COI).

For more information, please visit the following website.